Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC.CYPH · Entity 6392 | Director | August 26, 2026 | August 27, 2026 |
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYPHERPUNK TECHNOLOGIES INC.
Report date August 26, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,500 |
Reported balance
After 2026-08-26 transaction · row 1
1 source rowRow 1 · 2026-08-26 · Sale · Disposed 20,000 · Balance 132,500 |
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 40,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Paratek Pharmaceuticals, Inc.
Report date September 21, 2023 · Filed September 21, 2023
Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2023-09-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-21 · Disposition to issuer · Disposed 49,250 · Balance 20,000 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, F2: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. F3: Due to administrative error, the Reporting Person's previous Form 4 filings over-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F5: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2031-02-18 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2030-02-19 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.23 · Expires 2029-02-26 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.10 · Expires 2027-02-01 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-21 · Disposition to issuer · Disposed 6,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2026-02-03 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-21 · Disposition to issuer · Disposed 12,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.07 · Expires 2025-02-03 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash,
F2: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.
F3: Due to administrative error, the Reporting Person's previous Form 4 filings over-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person.
F4: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,
F5: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.
F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Aug 27, 2026 20:30 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | SaleCommon Stock | 20,000 | $1.72 | $34,400.00 |
DisclosureSEC source: 0001104659-26-102467 · tm2624205-1_4seq1.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,500 Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:57 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-080495 · tm2619727-5_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were issued under the Company's 2025 Equity Incentive Plan for no consideration. F2 · derivative.exercise_date: The RSUs will vest on June 15, 2027. Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock no later than the fifteenth (15th) day of the third (3rd) calendar month following the calendar year in which the date of grant occurs. F2 · derivative.expiration_date: The RSUs will vest on June 15, 2027. Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock no later than the fifteenth (15th) day of the third (3rd) calendar month following the calendar year in which the date of grant occurs. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 22:06 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 104,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-029646 · tm269084-10_4seq1.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 104,500 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share. F2 · derivative.exercise_date: The December 2025 RSUs vested at issuance on their grant date. F2 · derivative.expiration_date: The December 2025 RSUs vested at issuance on their grant date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 22:06 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionCommon Stock | 104,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-029646 · tm269084-10_4seq1.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 104,500 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share. F1 · price: 104,500 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share. Read SEC document |
| December 26, 2025 Filed Dec 30, 2025 21:33 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 83,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-125256 · tm2534450-5_4seq1.xml · derivative · entry 3 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents RSUs to be settled on a 1 for 1 basis for shares of Company Common Stock. The November 2025 RSUs were awarded pursuant to the Company's 2022 Equity Incentive Plan for no consideration. F1 · kind: 83,000 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 (the "November 2025 RSUs") were settled on December 26, 2025 on a net issue basis such that, of the 83,000 shares of the Company's common stock, par value $0.001 per share ("Common Stock") underlying the November 2025 RSUs, the Company issued to the reporting person on such settlement date only 48,000 of such shares, and the Company withheld on such settlement date the remaining 35,000 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the November 2025 RSUs. None of such 35,000 shares of Common Stock so withheld by the Company constituted sales of such shares by the reporting person. F3 · derivative.exercise_date: The November 2025 RSUs vested at issuance on their grant date. On December 26, 2025, the Compensation Committee of the Board of Directors took action to permit the early settlement of the November 2025 RSUs on a net issue basis as further described in footnote (1) above. F3 · derivative.expiration_date: The November 2025 RSUs vested at issuance on their grant date. On December 26, 2025, the Compensation Committee of the Board of Directors took action to permit the early settlement of the November 2025 RSUs on a net issue basis as further described in footnote (1) above. Read SEC document |
| December 26, 2025 Filed Dec 30, 2025 21:33 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Tax withholdingCommon Stock | 35,000 | $1.20 | $42,000.00 |
DisclosureSEC source: 0001104659-25-125256 · tm2534450-5_4seq1.xml · nonDerivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 F1 · kind: 83,000 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 (the "November 2025 RSUs") were settled on December 26, 2025 on a net issue basis such that, of the 83,000 shares of the Company's common stock, par value $0.001 per share ("Common Stock") underlying the November 2025 RSUs, the Company issued to the reporting person on such settlement date only 48,000 of such shares, and the Company withheld on such settlement date the remaining 35,000 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the November 2025 RSUs. None of such 35,000 shares of Common Stock so withheld by the Company constituted sales of such shares by the reporting person. Read SEC document |
| December 26, 2025 Filed Dec 30, 2025 21:33 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionCommon Stock | 83,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-125256 · tm2534450-5_4seq1.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 83,000 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 (the "November 2025 RSUs") were settled on December 26, 2025 on a net issue basis such that, of the 83,000 shares of the Company's common stock, par value $0.001 per share ("Common Stock") underlying the November 2025 RSUs, the Company issued to the reporting person on such settlement date only 48,000 of such shares, and the Company withheld on such settlement date the remaining 35,000 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the November 2025 RSUs. None of such 35,000 shares of Common Stock so withheld by the Company constituted sales of such shares by the reporting person. F2 · price: Represents RSUs to be settled on a 1 for 1 basis for shares of Company Common Stock. The November 2025 RSUs were awarded pursuant to the Company's 2022 Equity Incentive Plan for no consideration. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 21:33 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | GrantRestricted Stock Units · Derivative | 104,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-125256 · tm2534450-5_4seq1.xml · derivative · entry 4 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,500 Underlying: Common Stock · 104,500 shares Expires not disclosed F4 · derivative.exercise_price: Represents RSUs to be settled on a 1 for 1 basis for shares of Company Common Stock. The RSUs (the "December 2025 RSUs") were awarded pursuant to the Company's 2025 Equity Incentive Plan for no consideration. F5 · derivative.exercise_date: The December 2025 RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the December 2025 RSU award and applicable tax withholdings, the Company shall settle the December 2025 RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. F5 · derivative.expiration_date: The December 2025 RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the December 2025 RSU award and applicable tax withholdings, the Company shall settle the December 2025 RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:54 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | GrantRestricted Stock Units · Derivative | 83,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-111433 · tm2531210-3_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were awarded pursuant to the Company's 2022 Equity Incentive Plan for no consideration. F2 · derivative.exercise_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. F2 · derivative.expiration_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:24 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-106333 · tm2425653-3_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 02:36 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001104659-24-009030 · tm244775-8_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-01-29 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $24.07 | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · derivative · entry 9 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-02-03 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $14.05 | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · derivative · entry 8 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-02-03 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 6,000 | Not disclosed Strike: $15.10 | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · derivative · entry 7 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-02-01 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $14.15 | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · derivative · entry 6 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $7.23 | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · derivative · entry 5 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2029-02-26 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 7,000 | Not disclosed Strike: $3.51 | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · derivative · entry 4 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2030-02-19 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 7,000 | Not disclosed Strike: $7.61 | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · derivative · entry 3 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2031-02-18 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · nonDerivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F5 · price: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerCommon Stock | 49,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019349 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, F2 · price: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. F3 · balance_after: Due to administrative error, the Reporting Person's previous Form 4 filings over-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:31 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001104659-23-095361 · tm2324823-7_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-08-23 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of November 23, 2023, February 23, 2024, May 23, 2024 and August 23, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:12 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001104659-23-041747 · tm2311741-6_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-03-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023 for so long as the reporting person continues to be a director, consultant or service provider of the Company until the Option is fully vested. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:49 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001140361-23-010157 · form4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 21:07 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000101 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 8, 2023, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 20:54 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 50,000 | $1.43 | $71,580.00 |
DisclosureSEC source: 0001567619-23-001284 · doc1.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. F2 · ownership.nature: These shares are held directly by the Dietz Family Trust, for which the reporting person and his spouse serve as co-trustees. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:31 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 22,500 | $1.17 | $26,302.50 |
DisclosureSEC source: 0001140361-22-047071 · form4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1628 to $1.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. Read SEC document |
| September 01, 2022 Filed Sep 3, 2022 01:24 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097616 · tm2225099-5_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001140361-22-009257 · form4.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-03-10 F2 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 11, 2022 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-009257 · form4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 11, 2022. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 17:14 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000163 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 16, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:48 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001104659-22-011051 · tm225302-8_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2022, the Vesting Start Date. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 18:10 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 1,000 | $8.50 | $8,500.00 |
DisclosureSEC source: 0001209191-21-026382 · doc4.xml · nonDerivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 18:10 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 1,500 | $8.48 | $12,720.00 |
DisclosureSEC source: 0001209191-21-026382 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:25 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0001209191-21-020577 · doc4.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-03-11 F2 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 12, 2021 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:25 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020577 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 12, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:27 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0000904454-21-000228 · edgar.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-02-18 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 18, 2021, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:27 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000228 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 18, 2021, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 00:12 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 37,300 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-21-001649 · tm211724d4_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,300 Underlying: Common Stock · 37,300 shares Expires 2031-01-03 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2021, the Vesting Start Date. Read SEC document |
| August 10, 2020 Filed Aug 13, 2020 01:17 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001104659-20-094194 · a4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-08-09 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three month anniversary of August 10, 2020, the Vesting Start Date. Read SEC document |
| April 09, 2020 Filed Apr 14, 2020 00:21 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001104659-20-046078 · a4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-04-09 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of April 9, 2020, the Vesting Start Date. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 17:17 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 1,000 | $4.95 | $4,950.00 |
DisclosureSEC source: 0001209191-20-019685 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:22 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-20-018977 · doc4.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-03-11 F2 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 12, 2020 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:22 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018977 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 12, 2020. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:07 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001104659-20-029236 · a4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2020, the Vesting Start Date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:31 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000904454-20-000238 · edgar.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-02-19 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 19, 2020, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:31 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000238 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 19, 2020, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 08:17 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 4,000 | $13.94 | $55,760.00 |
DisclosureSEC source: 0001209191-20-003153 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.89 to $13.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 20:43 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001104659-19-035074 · a4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of June 11, 2019, the Vesting Start Date. Read SEC document |
| April 23, 2019 Filed Apr 23, 2019 18:53 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 5,000 | $11.10 | $55,495.00 |
DisclosureSEC source: 0001209191-19-025623 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.085 to $11.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. Read SEC document |
| April 22, 2019 Filed Apr 22, 2019 21:34 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 5,000 | $11.05 | $55,250.00 |
DisclosureSEC source: 0001209191-19-025563 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.